KPV (Lysine-Proline-Valine)
KPV tripeptide; Lys-Pro-Val; α-MSH(11-13); alpha-MSH C-terminal tripeptide
The Ground Truth Score
four plain questions, never one numberStrong animal/lab data, zero human trials
Bottom line
KPV has genuinely compelling cell-line and mouse anti-inflammatory data, but not a single completed human trial backs any of its gut, skin, or recovery claims, so it remains a promising hypothesis, not a proven therapy.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓REPORTED (not prescribed, not trial-validated): oral/sublingual roughly 250-1000 mcg/day (commonly 500 mcg once or twice daily) for gut applications; subcutaneous roughly 200-500 mcg/day, often starting ~200 mcg and titrating up after the first week.
Reported, not prescribed. Verify your vial and your math.
First documented human use
No controlled human trial of KPV has been completed or registered. The compound's human exposure to date is entirely off-label/gray-market use through compounding pharmacies and research-chemical vendors (broadly circulating in the peptide community from roughly the early 2020s); there is no published first-in-human study, no dated clinical milestone, and no ClinicalTrials.gov interventional record specific to the KPV tripeptide. That blank is the single most important fact on this page.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- A 3-amino-acid fragment (Lys-Pro-Val) of the C-terminus of alpha-MSH that retains anti-inflammatory activity while shedding the parent hormone's pigmentation and appetite effects.
- Reported (mechanistically and in animals) to dampen NF-kB and MAPK inflammatory signaling and lower pro-inflammatory cytokines.
- Marketed for inflammatory gut conditions, skin inflammation/wound healing, and general recovery.
- Notable for apparent oral bioavailability via the PepT1 transporter, unusual for a peptide.
- Promoted as having a corticosteroid-like anti-inflammatory effect without the steroid side-effect burden, a claim that rests on preclinical data only.
The data behind each bullet
What actually backs it
KPV reduces intestinal inflammation in animal colitis models and is transported into cells via PepT1, inhibiting NF-kB and MAP-kinase signaling.
Landmark preclinical study (Dalmasso et al., Gastroenterology, 2008): human intestinal cell LINES (Caco2-BBE, HT29) and Jurkat T cells plus DSS- and TNBS-induced colitis in MICE. Oral KPV reduced colitis incidence and cytokine expression. This is cell + animal data, not a human trial.
PubMed: PepT1-mediated KPV uptake reduces intestinal inflammation (Dalmasso 2008) ↗KPV broadly exerts anti-inflammatory and antimicrobial effects as an alpha-MSH-derived peptide.
Mechanistic and animal/in-vitro literature on alpha-MSH and its C-terminal tripeptide; reviews describe anti-inflammatory/antimicrobial activity. No human efficacy trials of the KPV tripeptide itself.
PubMed search: KPV tripeptide inflammation ↗KPV protects skin keratinocytes from particulate-matter-induced apoptosis/inflammation and can be delivered transdermally.
In-vitro keratinocyte study (50 ug/mL KPV restored viability after PM10 exposure) and an ex-vivo human-skin iontophoretic delivery paper. These are cell-culture and skin-permeation experiments, not clinical outcomes.
PubMed search: KPV keratinocyte skin peptide ↗No registered human clinical trial exists for KPV.
ClinicalTrials.gov returns no interventional study of the KPV tripeptide for inflammation, colitis, or skin/gut endpoints as of June 2026. All human-use claims are extrapolated from preclinical work.
ClinicalTrials.gov search: KPV peptide ↗KPV is restricted from US compounding pending review due to insufficient safety characterization.
FDA placed KPV-class peptide bulk substances in Category 2 of the interim 503A bulks list (2023) citing significant-safety-risk/insufficient-data concerns; KPV is slated for Pharmacy Compounding Advisory Committee (PCAC) review at the July 23-24, 2026 meeting.
FDA: July 23-24, 2026 PCAC meeting ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
Assumed mechanism (KPV is NOT an approved drug): KPV is the C-terminal tripeptide of alpha-MSH. It is thought to enter cells, including intestinal epithelial and immune cells, partly via the PepT1 di/tripeptide transporter, then act intracellularly to inhibit IkB kinase and reduce NF-kB nuclear translocation, while also dampening MAPK signaling and inflammasome-driven cytokines (e.g., IL-1beta). The net assumed effect is lower pro-inflammatory cytokine output and reduced immune-cell activation, without the pigmentation/appetite effects of full-length alpha-MSH. This model is built from cell and animal experiments, not human pharmacology.
Dosing & handling
What users and clinicians report
REPORTED (not prescribed, not trial-validated): oral/sublingual roughly 250-1000 mcg/day (commonly 500 mcg once or twice daily) for gut applications; subcutaneous roughly 200-500 mcg/day, often starting ~200 mcg and titrating up after the first week. Cycles of about 4-8 weeks are typical. Topical/transdermal use is also described for skin. These figures come from vendor guides and clinic blogs, not human studies.
No dose has been established in any human trial, every number above is community/vendor convention, not medicine. Dosing varies widely by source, the gut rationale leans on oral delivery while injectable use has even less human grounding, and unverified product purity means the actual delivered dose is uncertain. Treat all of it as experimental.
Timing & food
For gut applications the rationale for oral/sublingual dosing is local and PepT1-mediated GI uptake; some users take it on an empty stomach or away from large meals on the theory of improving absorption and contact with gut lining, though no human data confirm a food-effect. Given the estimated short (~4-6 h) half-life, twice-daily dosing (roughly every 12 hours) is the common pattern used to maintain coverage. Timing conventions are extrapolated, not trial-derived.
Half-life
Not formally established in humans. Vendor/clinic sources cite an estimated circulating half-life on the order of 4-6 hours (used to justify twice-daily dosing), but this figure is not anchored to a published human pharmacokinetic study and should be treated as an estimate.
Reconstitution sensitivity
Supplied as a lyophilized powder; reconstituted with bacteriostatic water (community concentrations commonly ~1-5 mg/mL). Reported handling: add diluent gently down the vial wall (avoid forceful agitation), store reconstituted solution refrigerated at 2-8 C and use within roughly 4 weeks, keep away from light, and avoid heat excursions/freeze-thaw which can degrade peptide. Unreconstituted powder is described as stable refrigerated/cool for many months. As with all gray-market peptides, real-world stability depends on unverified product quality.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Modest. KPV has a real but secondary presence in the peptide community, well behind heavyweights like BPC-157 and TB-500. Discussion clusters in gut-health and biohacking circles; claims of explosive Reddit growth trace largely to vendor/affiliate content rather than organic, verifiable user volume.
Consistency
Mixed. The most consistent positive reports are for gut/IBD-type symptoms and some skin/inflammation use; recovery and systemic anti-inflammatory claims are more scattered. Reports also disagree on the best route (oral vs sublingual vs subcutaneous), and a meaningful share of users describe no clear effect.
Source credibility
Low-to-moderate after discounting. A large fraction of accessible KPV content is published by sellers, compounding clinics, and affiliate sites with a commercial interest, which inflates apparent enthusiasm. Genuinely independent, non-commercial user reports exist but are fewer and rarely include objective markers, so the credible signal is thin.
- Gut-focused users most often report KPV as part of a 'gut-healing' stack (commonly with BPC-157), and a subset describe genuinely reduced bloating, urgency, or flare symptoms, though it is hard to separate from diet changes and co-administered peptides.
- Many report it as subtle: anti-inflammatory and 'calming' rather than dramatic, with effects that build over weeks rather than being felt acutely.
- Reports diverge on the best route, some find oral/sublingual more reliable for gut symptoms, others prefer subcutaneous; a notable contingent reports no clear benefit at all.
- Tolerability is generally described as good, with the main complaints being injection-site irritation or mild GI upset; the recurring caution in serious threads is that the human evidence simply isn't there and product purity is uncertain.
Placebo risk, Moderate
Moderate placebo risk: the headline benefits people chase, reduced gut discomfort, less bloating, feeling "less inflamed," better skin, are largely subjective and fluctuate naturally with diet, stress, and disease flares. A minority track objective endpoints (e.g., calprotectin, visible skin lesions), which would lower placebo risk, but most use is self-assessed, and KPV is usually stacked with other interventions that confound attribution.
Risk panel
What could go wrong
Adverse events
Reported adverse effects (from anecdote and vendor/clinic reporting, not controlled trials) are generally mild: injection-site irritation/redness with the subcutaneous form, occasional mild transient nausea or digestive change with oral use, and rare systemic complaints (malaise/hypersensitivity). No deaths, organ toxicity, or dose-limiting events are documented in the peer-reviewed (animal) literature. Critically, these frequency figures circulating online are not from human trials and should be treated as unverified.
Theoretical concerns
As a short fragment of endogenous alpha-MSH that acts on inflammatory signaling (NF-kB/MAPK) and immune-cell function, broad or chronic immunomodulation/immunosuppression is the main theoretical concern, potentially blunting useful immune responses or masking infection. Any peptide carries theoretical immunogenicity risk, and gray-market product can contain impurities or endotoxin that drive their own reactions independent of KPV.
Contraindications
Practitioners who use it typically screen out active infection, autoimmune disease, and pregnancy/breastfeeding before starting, a sensible precaution given the immunomodulatory mechanism, NOT an evidence-based contraindication list. Because there is no human safety dataset, anyone immunocompromised, pregnant, on immunosuppressants, or with active malignancy should regard KPV as untested and avoid it.
Honest unknowns
Nearly everything that matters in humans is unknown: no formal human toxicology, no drug-interaction studies, no long-term safety data, no carcinogenicity/reproductive data, and no validated dosing. Product identity and purity from research-chemical and compounding sources are unverified. The FDA's Category 2 placement signals the agency itself considers human safety insufficiently characterized.
Confound watch
KPV is rarely run alone. Users commonly stack it with BPC-157 and/or TB-500 (the standard "gut/healing" trio), and frequently layer dietary changes, elimination diets, glutamine, or anti-inflammatory supplements, plus prescription IBD therapy in gut cases. Any perceived benefit is easily attributable to those co-interventions, regression to the mean of a flaring condition, or placebo rather than KPV itself.
History
Discovery → first use → status
Heads up: the legal status is moving (2026)
This one got put on the FDA's Category 2 'do not compound' list back in 2023. In April 2026 the FDA moved to pull it back off that list, and there's a July 2026 advisory meeting weighing whether it can be legally compounded again. None of that is final, and none of it makes anything proven or safe. It just means the legal picture is changing fast, so check the date on anything you read about whether this is allowed.
FDA peptide compounding update, 2026 ↗- 1980s-1990salpha-MSH and its C-terminal tripeptide region (KPV) characterized for anti-inflammatory activity in early peptide/immunology research.
- 2008Dalmasso et al. publish the landmark KPV colitis study in Gastroenterology, human cell lines + mouse DSS/TNBS colitis, proposing KPV as a PepT1-transported anti-inflammatory candidate for IBD.
- 2017Transdermal iontophoretic delivery of KPV across microporated human skin published (delivery/permeation, ex-vivo); period also yields rodent work reporting no notable toxicity at high doses.
- 2023FDA places KPV-class peptides into Category 2 of the interim 503A bulks list, effectively restricting legal compounding pending review.
- July 2026KPV scheduled for FDA Pharmacy Compounding Advisory Committee (PCAC) review (July 23-24, 2026), the key near-term regulatory event; no human trial has yet been completed.
Verification
The COA standard, applied
Confirmed the foundational study is preclinical (Dalmasso et al., Gastroenterology 2008: human cell lines + mouse DSS/TNBS colitis, PMID 18061177). Confirmed via multiple independent sources that no registered human clinical trial of KPV exists on ClinicalTrials.gov. Confirmed FDA placed KPV-class peptides in Category 2 of the 503A interim bulks list (2023) and scheduled PCAC review for July 23-24, 2026 (FDA meeting page). Skin/keratinocyte and transdermal-delivery work confirmed as in-vitro/ex-vivo. Citation URLs are valid PubMed/ClinicalTrials.gov/FDA endpoints; no PMIDs, titles, authors, or statistics were invented. Online adverse-event and Reddit-volume percentages were treated as unverified vendor/marketing claims, not data.
The full verification standard →Sources
Where this comes from
- Dalmasso et al., Gastroenterology 2008 (PMID 18061177), landmark KPV/PepT1 colitis study (cell + mouse) ↗· Foundational preclinical evidence; human cell lines and mouse colitis, NOT a human trial.
- PubMed search: KPV tripeptide inflammation ↗· Body of literature is overwhelmingly in-vitro and animal.
- PubMed search: KPV peptide keratinocyte skin ↗· Skin/keratinocyte work is cell-culture and ex-vivo skin permeation.
- ClinicalTrials.gov search: KPV peptide ↗· No registered interventional human trial of the KPV tripeptide as of June 2026.
- FDA Pharmacy Compounding Advisory Committee, July 23-24 2026 meeting ↗· KPV slated for PCAC review; reflects regulatory uncertainty and Category 2 history.
- FDA: Certain bulk drug substances that may present significant safety risks (Category 2 context) ↗· Background on the Category 2 restriction affecting compounded peptides including KPV.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.